232 related articles for article (PubMed ID: 35514988)
1. Lymphoplasma Exchange Improves Myasthenia Gravis Exacerbations: A Retrospective Study in a Chinese Center.
Ouyang S; Yin W; Zeng Q; Li B; Zhang J; Duan W; Li Y; Liang Y; Wang J; Tan H; Yang H
Front Immunol; 2022; 13():757841. PubMed ID: 35514988
[TBL] [Abstract][Full Text] [Related]
2. Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study.
Duan W; Jiang F; Cai H; Li B; Ouyang S; Yin W; Zeng Q; Yang H
Front Neurol; 2023; 14():1212868. PubMed ID: 37441608
[TBL] [Abstract][Full Text] [Related]
3. Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study.
McPherson T; Aban I; Duda PW; Farzaneh-Far R; Wolfe GI; Kaminski HJ; Cutter G; Lee I;
Muscle Nerve; 2020 Aug; 62(2):261-266. PubMed ID: 32369631
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials.
Weng S; Li J; Chen B; He L; Zhong Z; Huang L; Zhang S; Liu F; Jiang Q
Trials; 2022 Apr; 23(1):365. PubMed ID: 35477531
[TBL] [Abstract][Full Text] [Related]
5. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Wu H; Chen L; Zhou X; Wu Y; Yan Y; Zhu Y; Zhao C; Xue Q
J Neuroimmunol; 2022 Nov; 372():577955. PubMed ID: 36054935
[TBL] [Abstract][Full Text] [Related]
6. Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis.
Duan W; Zhou H; Dong X; Li B; Li Y; Cai H; Zhou Q; Ouyang S; Yin W; Yang H
Front Neurol; 2022; 13():1018509. PubMed ID: 36303555
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis.
Wu H; Wang Z; Xi J; Liu J; Yan C; Song J; Wang L; Jing S; Wang Y; Zhao C
Eur Neurol; 2020; 83(5):500-507. PubMed ID: 32932253
[TBL] [Abstract][Full Text] [Related]
8. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
Howard JF; Vu T; Mantegazza R; Kushlaf H; Suzuki S; Wiendl H; Beasley KN; Liao S; Meisel A;
Muscle Nerve; 2024 May; 69(5):556-565. PubMed ID: 38380691
[TBL] [Abstract][Full Text] [Related]
10. Effect of efgartigimod on muscle group subdomains in participants with generalized myasthenia gravis: post hoc analyses of the phase 3 pivotal ADAPT study.
Bril V; Howard JF; Karam C; De Bleecker JL; Murai H; Utsugisawa K; Ulrichts P; Brauer E; Zhao S; Mantegazza R; Vu T;
Eur J Neurol; 2024 Jan; 31(1):e16098. PubMed ID: 37843174
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with maintenance therapeutic plasma exchange in refractory generalized myasthenia gravis.
Sheckley H; Malhotra K; Katyal N; Narula N; Govindarajan R
J Clin Apher; 2021 Oct; 36(5):727-736. PubMed ID: 34241920
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of leflunomide combined with low-dose prednisone in treatment of myasthenia gravis: a retrospective study.
Qiu L; Chen P; Ou C; Deng J; Huang Z; Lin Z; Ma Q; Huang X; Yu L; Ran H; Liu W
Acta Neurol Belg; 2024 Feb; 124(1):175-182. PubMed ID: 37656361
[TBL] [Abstract][Full Text] [Related]
13. QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis.
Howard JF; Freimer M; O'Brien F; Wang JJ; Collins SR; Kissel JT;
Muscle Nerve; 2017 Aug; 56(2):328-330. PubMed ID: 28010051
[TBL] [Abstract][Full Text] [Related]
14. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
Bourque PR; Pringle CE; Cameron W; Cowan J; Chardon JW
PLoS One; 2016; 11(8):e0159993. PubMed ID: 27490101
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
17. Palpebral portion of the orbicularis oculi muscle to repetitive nerve stimulation testing: A potential assessment indicator in patients with generalized myasthenia gravis.
Yan C; Song J; Pang S; Yi F; Xi J; Zhou L; Ding D; Wang W; Qiao K; Zhao C
J Clin Neurosci; 2018 Feb; 48():238-242. PubMed ID: 29239825
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy and immunoregulatory effect of Qiangji Jianli Capsule for patients with myasthenia gravis: Study protocol for a series of randomized, controlled N-of-1 trials.
Weng S; Fan Z; Qiu G; Liu F; Huang L; Li J; Jiang X; Song Z; Gao Y; Zhong Z; He L; Kang L; Wu Y; Chen B; Jiang Q
Medicine (Baltimore); 2020 Dec; 99(51):e23679. PubMed ID: 33371107
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka KV
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
